[Retracted] PRR15 Is a Novel Diagnostic and Prognostic Biomarker in Papillary Thyroid Cancer and Modulates the Tumor Microenvironment

Table 1

Association of PRR15 with clinicopathological characteristics of PTC patients.

Characteristics	The low expression of PRR15	The high expression of PRR15
N	255	255
Gender, n (%)			0.691
Female	183 (35.9%)	188 (36.9%)
Male	72 (14.1%)	67 (13.1%)
Age, n (%)			0.723
≤45	118 (23.1%)	123 (24.1%)
>45	137 (26.9%)	132 (25.9%)
M stage, n (%)			0.505
M0	138 (46.8%)	148 (50.2%)
M1	3 (1%)	6 (2%)
N stage, n (%)			0.025
N0	123 (26.7%)	106 (23%)
N1	99 (21.5%)	132 (28.7%)
T stage, n (%)			0.500
T1	65 (12.8%)	78 (15.4%)
T2	85 (16.7%)	82 (16.1%)
T3	89 (17.5%)	86 (16.9%)
T4	14 (2.8%)	9 (1.8%)
Age, median (IQR)	48 (35.5, 60)	46 (34, 56)	0.096